GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

Kennedy Jr. has his way, get ready for even more anti-pharma rhetoric and potential instability at the Food and Drug ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

There’s no better time to be alive, only if we can learn to thrive amidst constant change and disruption” muses health tech ...

When Hurricane Helene damaged western North Carolina in September, filling medical facilities with people who couldn't be ...

Drugmaker Abbott India reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications. The company, which makes the ...

Several companies such as Shriram Finance, Symphony, etc. will be in focus today on account of corporate actions.

Dividend, stock split: Navin Fluorine International, Nuvama Wealth Management, Share India Securities, Shriram Finance Ltd, ...

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

Report on how AI is redefining market landscape - The global gastroparesis drugs market size is estimated to grow by USD 1.42 ...

The growing demand for alopecia treatments is mainly driven by the rising global prevalence of alopecia, influenced by various factors, as well as increasing research and development efforts in ...